Qing Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qing Zhang has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Wenyou Fang
Anhui Province Key Laboratory of Research & Development of Chinese Medicine, Anhui Province Key Laboratory of Pharmaceutical Technology and Application, School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China
4 shared publications- Rongfeng Hu
School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China
3 shared publications - Wenjie Lu
School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China
3 shared publications Nan Wang
2 shared publicationsRongfeng Hu
Anhui Province Key Laboratory of Research & Development of Chinese Medicine, Anhui Province Key Laboratory of Pharmaceutical Technology and Application, School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China
2 shared publicationsShengqi Chen
2 shared publications
Latest Publications
- 6 August 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 268 (Pt 2) , 116053
Two birds with one stone: Charge flip assisted colon-targeting hybrid nanoplatform for both drug delivery and proinflammatory factor scavenging
- 6 August 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 268 (Pt 2) , 116053
Two birds with one stone: Charge flip assisted colon-targeting hybrid nanoplatform for both drug delivery and proinflammatory factor scavenging
- 29 July 2024
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 7 (15) , 17795-17803
Carbon Dots Dually Doped with Fe and Co for Visual Detection of H2O2 and Glutathione
- 29 July 2024
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 7 (15) , 17795-17803
Carbon Dots Dually Doped with Fe and Co for Visual Detection of H2O2 and Glutathione
- 9 July 2022
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 74
5-aminosalicylic acid pH sensitive core-shell nanoparticles targeting ulcerative colitis
- 9 July 2022
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 74
5-aminosalicylic acid pH sensitive core-shell nanoparticles targeting ulcerative colitis
- 21 January 2021
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 9 (6) , 2279-2294
Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment
Antibody-functionalized targeted nanocarriers to deliver chemotherapeutics have been widely explored. However, it remains highly desirable to understand and apply the antitumor potential of antibodies integrated in hybrid composite nanoplatforms. Herein, mesoporous silica nanoparticles, a supported lipid bilayer and cetuximab were integrated to fabricate a hybrid nanoplatform for effectively encapsulating and selectively delivering 5-fluorouracil (5-FU) against colorectal cancer (CRC) cells. The specially designed nanoplatform exhibited superior properties, such as satisfying size distribution, dispersity and stability, drug encapsulation, controlled release, and cellular uptake. Interestingly, the modification of cetuximab onto nanoplatforms without drug loading can significantly inhibit the migration and invasion of CRC cells through suppressing the epidermal growth factor receptor (EGFR)-associated signaling pathway. Furthermore, delivery of 5-FU by using this nanoplatform can remarkably induce cytotoxicity, cell cycle arrest, and cell apoptosis for CRC cells with high EGFR expression. Overall, this nanostructured platform can dramatically improve the tumor killing effects of encapsulated chemotherapeutics and present antimigration effects derived from the antibody modified on it. Moreover, in vivo biodistribution experiments demonstrated the superior tumor targeting ability of the targeted nanoparticles. Thus, this targeted nanoplatform has substantial potential in combinational therapy of antibodies and chemotherapy agents against colorectal cancer.
- 21 January 2021
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 9 (6) , 2279-2294
Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment
Antibody-functionalized targeted nanocarriers to deliver chemotherapeutics have been widely explored. However, it remains highly desirable to understand and apply the antitumor potential of antibodies integrated in hybrid composite nanoplatforms. Herein, mesoporous silica nanoparticles, a supported lipid bilayer and cetuximab were integrated to fabricate a hybrid nanoplatform for effectively encapsulating and selectively delivering 5-fluorouracil (5-FU) against colorectal cancer (CRC) cells. The specially designed nanoplatform exhibited superior properties, such as satisfying size distribution, dispersity and stability, drug encapsulation, controlled release, and cellular uptake. Interestingly, the modification of cetuximab onto nanoplatforms without drug loading can significantly inhibit the migration and invasion of CRC cells through suppressing the epidermal growth factor receptor (EGFR)-associated signaling pathway. Furthermore, delivery of 5-FU by using this nanoplatform can remarkably induce cytotoxicity, cell cycle arrest, and cell apoptosis for CRC cells with high EGFR expression. Overall, this nanostructured platform can dramatically improve the tumor killing effects of encapsulated chemotherapeutics and present antimigration effects derived from the antibody modified on it. Moreover, in vivo biodistribution experiments demonstrated the superior tumor targeting ability of the targeted nanoparticles. Thus, this targeted nanoplatform has substantial potential in combinational therapy of antibodies and chemotherapy agents against colorectal cancer.